Masaaki Ito1, Akihiro Kobayashi2, Shin Fujita3, Junki Mizusawa4, Yukihide Kanemitsu5, Yusuke Kinugasa6, Koji Komori7, Masayuki Ohue8, Mitsuyoshi Ota9, Yoshihiro Akazai10, Manabu Shiozawa11, Takashi Yamaguchi12, Takayuki Akasu13, Yoshihiro Moriya14. 1. Department of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: maito@east.ncc.go.jp. 2. Department of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan. 3. Department of Surgery, Tochigi Cancer Center, Utsunomiya, Japan. Electronic address: sifujita@tcc.pref.tochigi.lg.jp. 4. JCOG Data Center, National Cancer Center Hospital, Tokyo, Japan. 5. Colorectal Surgery Division, National Cancer Center Hospital Tokyo, Japan. 6. Department of Surgery, Shizuoka Cancer Center, Shizuoka, Japan. 7. Department of Surgery, Aichi Cancer Center, Nagoya, Japan. 8. Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan. 9. Department of Surgery, Yokohama City University Medical Center Yokohama, Japan. 10. Department of Surgery, Okayama Saiseikai General Hospital, Okayama, Japan. 11. Department of Surgery, Kanagawa Cancer Center, Yokohama, Japan. 12. Department of Surgery, Kyoto Medical Center, Kyoto, Japan. 13. Department of Surgery, The Imperial Household Agency Hospital, Tokyo, Japan. 14. Department of Surgery, Japanese Red Cross Medical Center, Tokyo, Japan.
Abstract
BACKGROUND: Postoperative urinary dysfunction is a major complication of rectal cancer surgery. A randomized controlled trial (JCOG0212) concluded that the noninferiority of mesorectal excision alone to mesorectal excision with lateral lymph node dissection was not confirmed in terms of relapse-free survival. METHODS:Eligibility criteria included histologically proven clinical stage II/III rectal cancer, a main lesion located in the rectum with the lower margin below the peritoneal reflection, and the absence of lateral lymph node enlargement. After confirming R0 resection by mesorectal excision, patients were randomized intraoperatively. The residual urine volume was measured three times. Urinary dysfunction was defined as ≥50 mL residual urine occurring at least once or no measurement of residual urinary volume. This trial was registered with the UMIN Clinical Trials Registry, number C000000034. RESULTS: In the mesorectal excision alone and the mesorectal excision with lateral lymph node dissection groups, the incidence of early urinary dysfunction were 58% and 59%, respectively. A tumor location in the lower rectum (vs. upper rectum) and a blood loss of ≥500 mL (vs. <500 mL) were associated with an increased risk of early urinary dysfunction. However, only blood loss was independently predictive of early urinary dysfunction (relative risk, 1.25 [95% CI: 1.10-1.55], p = .04). CONCLUSIONS:Mesorectal excision with lateral lymph node dissection is not associated with a significant increase in the incidence of urinary dysfunction. Urinary dysfunction is associated with tumor location and blood loss.
RCT Entities:
BACKGROUND:Postoperative urinary dysfunction is a major complication of rectal cancer surgery. A randomized controlled trial (JCOG0212) concluded that the noninferiority of mesorectal excision alone to mesorectal excision with lateral lymph node dissection was not confirmed in terms of relapse-free survival. METHODS: Eligibility criteria included histologically proven clinical stage II/III rectal cancer, a main lesion located in the rectum with the lower margin below the peritoneal reflection, and the absence of lateral lymph node enlargement. After confirming R0 resection by mesorectal excision, patients were randomized intraoperatively. The residual urine volume was measured three times. Urinary dysfunction was defined as ≥50 mL residual urine occurring at least once or no measurement of residual urinary volume. This trial was registered with the UMIN Clinical Trials Registry, number C000000034. RESULTS: In the mesorectal excision alone and the mesorectal excision with lateral lymph node dissection groups, the incidence of early urinary dysfunction were 58% and 59%, respectively. A tumor location in the lower rectum (vs. upper rectum) and a blood loss of ≥500 mL (vs. <500 mL) were associated with an increased risk of early urinary dysfunction. However, only blood loss was independently predictive of early urinary dysfunction (relative risk, 1.25 [95% CI: 1.10-1.55], p = .04). CONCLUSIONS: Mesorectal excision with lateral lymph node dissection is not associated with a significant increase in the incidence of urinary dysfunction. Urinary dysfunction is associated with tumor location and blood loss.
Authors: Tania C Sluckin; Sanne-Marije J A Hazen; Karin Horsthuis; Regina G H Beets-Tan; Corrie A M Marijnen; Pieter J Tanis; Miranda Kusters Journal: Insights Imaging Date: 2022-10-20